A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
Phase 1
18–60
5 sites in CA, FL, MO +1
About this study
This Phase 1 study is focused on people with healthy volunteers. The primary outcome being measured is Number of Participants Who Discontinue Study Treatment Due to an AE.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Secondary: Apparent Clearance (CL/F) of MK-4082, Apparent Terminal Half-life (t1/2) of MK-4082, Change from Baseline in Body Mass Index (BMI), Change from Baseline in Body Weight, Maximum Plasma Concentration (Cmax) of MK-4082, Time to Maximum Plasma Concentration (Tmax) of MK-4082